Qiagen (NYSE:QGEN - Free Report) - Equities research analysts at William Blair reduced their Q1 2025 earnings per share estimates for Qiagen in a report issued on Friday, February 7th. William Blair analyst A. Brackmann now anticipates that the company will post earnings of $0.49 per share for the quarter, down from their prior estimate of $0.50. The consensus estimate for Qiagen's current full-year earnings is $2.28 per share. William Blair also issued estimates for Qiagen's Q2 2025 earnings at $0.56 EPS, Q3 2025 earnings at $0.58 EPS, Q4 2025 earnings at $0.61 EPS, FY2025 earnings at $2.26 EPS, Q1 2026 earnings at $0.54 EPS, Q2 2026 earnings at $0.61 EPS, Q3 2026 earnings at $0.62 EPS, Q4 2026 earnings at $0.66 EPS and FY2026 earnings at $2.43 EPS.
A number of other brokerages have also recently commented on QGEN. UBS Group reduced their price objective on Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a research note on Friday. HSBC downgraded shares of Qiagen from a "buy" rating to a "hold" rating and set a $47.64 price target for the company. in a research report on Thursday, October 17th. Morgan Stanley reaffirmed an "equal weight" rating and set a $46.67 price target (down previously from $48.61) on shares of Qiagen in a research report on Monday, January 6th. Hsbc Global Res raised Qiagen to a "hold" rating in a report on Thursday, October 17th. Finally, Jefferies Financial Group reaffirmed a "buy" rating and issued a $52.50 price objective (up previously from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $48.78.
Read Our Latest Research Report on Qiagen
Qiagen Trading Down 1.4 %
Qiagen stock traded down $0.57 during trading on Monday, reaching $39.52. The company had a trading volume of 249,735 shares, compared to its average volume of 1,215,983. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. Qiagen has a 12-month low of $39.56 and a 12-month high of $49.30. The firm has a market capitalization of $8.77 billion, a price-to-earnings ratio of 110.02, a PEG ratio of 3.29 and a beta of 0.36. The stock's 50 day moving average price is $43.74 and its two-hundred day moving average price is $43.28.
Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.97%.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the company. Sanctuary Advisors LLC bought a new stake in shares of Qiagen in the 2nd quarter valued at about $647,000. Park Avenue Securities LLC acquired a new position in Qiagen during the third quarter worth $304,000. GAMMA Investing LLC lifted its position in shares of Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company's stock valued at $26,000 after buying an additional 500 shares during the last quarter. CWM LLC raised its position in shares of Qiagen by 11.5% in the third quarter. CWM LLC now owns 2,792 shares of the company's stock valued at $127,000 after purchasing an additional 287 shares during the period. Finally, Creative Planning lifted its holdings in Qiagen by 12.7% during the 3rd quarter. Creative Planning now owns 40,571 shares of the company's stock worth $1,849,000 after purchasing an additional 4,561 shares during the last quarter. Institutional investors own 70.00% of the company's stock.
About Qiagen
(
Get Free Report)
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
See Also
Before you consider Qiagen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.
While Qiagen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
